The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

There is no cure for COPD, but it can be managed and treated by working with your healthcare team to develop a plan to keep your COPD under control. Along with quitting smoking, staying up to date ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

In September, the FDA and Chinese regulators both approved Dupixent for patients with uncontrolled COPD and an eosinophilic phenotype. These approvals, along with the approval in Europe in June ...

The recent FDA approval of Dupixent for COPD with eosinophilic phenotype has reduced the risk associated with developing APG808, as both treatments target a similar patient population ...